AI Article Synopsis
- - The study compared the effectiveness of artesunate-sulfamethoxypyrazine-pyrimethamine to artemether-lumefantrine in treating uncomplicated Plasmodium falciparum malaria in Mali during 2003 and 2004.
- - Results indicated a higher cure rate for artesunate-sulfamethoxypyrazine-pyrimethamine (98.7%) compared to artemether-lumefantrine (89.6%), with both treatments showing high efficacy post-re-infection correction.
- - Both treatments were well-tolerated, with no serious adverse events reported, but artesunate-sulfamethoxypyrazine-pyrimethamine also helped prevent new infections effectively.*
Article Abstract
The choice of artemisinin-based combination that is being adopted for malaria treatment in sub-Saharan Africa may depend on several factors, including cost, efficacy, side effects, and simplicity of administration. We tested the hypothesis that artesunate-sulfamethoxypyrazine-pyrimethamine is as efficacious as the four-dose regimen of artemether-lumefantrine for treatment of Plasmodium falciparum malaria. The study was carried out during two transmission seasons (2003 and 2004) in Sotuba, Mali. Participants at least 6 months of age with uncomplicated P. falciparum malaria were randomly assigned to receive artesunate-sulfamethoxypyrazine-pyrimethamine or artemether-lumefantrine. Treatment efficacy was assessed using the World Health Organization 28-day protocol. A total of 606 (303 in each arm) patients were enrolled. The cure rate was higher for artesunate-sulfamethoxypyrazine-pyrimethamine than for artemether-lumefantrine (98.7% versus 89.6%; P < 0.0001). After correction for cases of re-infection, the cure rates were 100% and 99.0%, respectively (P = 0.08). No serious adverse events occurred. Artesunate-sulfamethoxypyrazine-pyrimethamine is well-tolerated and effective against P. falciparum malaria. It showed an additional benefit of preventing new infections.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Gossypol is a natural product with good antimalarial activity against Plasmodium falciparum clinical isolates.
Sci Rep
January 2025
West African Centre for Cell Biology of Infectious Pathogens, University of Ghana, Accra, Ghana.
Gossypol has demonstrated significant antimalarial activity against chloroquine-resistant and susceptible Plasmodium falciparum parasites. However, data on its potency in clinical isolates of P. falciparum remains limited.
View Article and Find Full Text PDFDistinct immunogenicity outcomes of DNA vaccines encoding malaria transmission-blocking vaccine target antigens Pfs230D1M and Pvs230D1.
Vaccine
January 2025
Department of Global Health, George Washington University, Washington, D.C., USA. Electronic address:
Transmission-blocking vaccines (TBVs) targeting sexual-stage antigens represent a critical tool for malaria control and elimination through inhibiting parasite development within mosquitoes. P230, displayed on the surface of gametocytes and gametes, plays a crucial role in gamete fertilization and is one of the leading TBV candidates for both Plasmodium falciparum and P. vivax.
View Article and Find Full Text PDFA combined school survey and reactive case detection reveals minimal local transmission of malaria in the Highlands Region of Papua New Guinea.
Malar J
January 2025
Swiss Tropical and Public Health Institute, Allschwil, Switzerland.
Background: The Highlands of Papua New Guinea are non-endemic for malaria compared to the rest of the country. This study aimed to explore the local transmission of malaria in the Highlands through a cross-sectional school survey coupled with reactive case detection.
Methods: Between July and November 2019, 5575 schoolchildren and 1048 household members were screened for malaria using Rapid Diagnostic Tests, subsequently validated by light microscopy.
Plasmodium falciparum histidine-rich protein 2 exhibits cell penetration and cytotoxicity with autophagy dysfunction.
Biosci Biotechnol Biochem
January 2025
Department of Bioresource Science, Faculty of Agriculture.
Plasmodium falciparum is a major cause of severe malaria. This protozoan infects human red blood cells and secretes large quantities of histidine-rich protein 2 (PfHRP2) into the bloodstream, making it a well-known diagnostic marker. Here, however, we identified PfHRP2 as a pathogenic factor produced by P.
View Article and Find Full Text PDFPlasmodium falciparum surf4.1 in clinical isolates: From genetic variation and variant diversity to in silico design immunopeptides for vaccine development.
PLoS One
January 2025
Department of Parasitology and Entomology, Faculty of Public Health, Mahidol University, Bangkok, Thailand.
SURFINs protein family expressed on surface of both infected red blood cell and merozoite surface making them as interesting vaccine candidate for erythrocytic stage of malaria infection. In this study, we analyze genetic variation of Pfsurf4.1 gene, copy number variation, and frequency of SURFIN4.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!